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ABSTRACT
Objectives: Angiotensin II receptor blockers (ARBs) were introduced into
the UK antihypertensive drug market at a premium price relative to other
antihypertensives during a period of evolving evidence about hypertension
treatment. This study aimed to determine the UK antihypertensive drug
budget impact as the ﬁrst ARB market launched in December 1994 and
what proportion of the increase was directly attributable to ARBs.
Methods: Prescriptions for oral antihypertensives were identiﬁed from
The Health Improvement Network database. Drug prices were based on
the Chemist & Druggist January 2005 pricelist estimating real expenditure
growth. Expenditure increases were disaggregated into the number of
patients receiving antihypertensive drug prescriptions, the number of anti-
hypertensive prescriptions per patient treated, and the average drug expen-
diture per antihypertensive prescription.
Results: The annual ARB prescription frequency increased from 0.04% in
1995 to 6.57% in 2004. Expenditure for antihypertensive drugs was
estimated at £465,862,416 in 1995 and £1,458,268,104 in 2004 (2005
values), reﬂecting a 213% real rate of increase. Use of ARBs accounted for
only 9.3% (range: 5.8%–12.5%) of the average drug expenditure. Treat-
ment prevalence rose from 11.30% in 1995 to 16.90% in 2004, while the
average number of antihypertensive drug prescriptions per patient
increased from 9.34 to 13.46 per year. The average expenditure per
antihypertensive drug prescription increased over time reﬂecting a product
shift toward more expensive therapies.
Conclusions: ARBs accounted for only 9.3% of the 213% increase in
antihypertensive drug expenditure after their introduction. A substantial
portion of the impact reﬂected increases in treatment prevalence and in the
number of prescriptions per patient.
Keywords: ARB, drug budget impact analysis, drug expenditure, hyper-
tension, prescribing trends.
Introduction
The ﬁrst angiotensin II receptor blocker (ARB) was introduced
into the UK antihypertensive drug market in December 1994.
Shortly after that, updated hypertension treatment guidelines
[1,2] recommended lower target goals for patients with hyper-
tension and target organ damage, diabetes, chronic renal disease,
or an increased risk of cardiovascular disease [1]. Systolic
blood pressure (BP) below 140 mm Hg and diastolic BP below
85 mm Hg were recommended as optimal for most patients. For
patients with diabetes, targets were less than 140 mm Hg
and less than 80 mm Hg, respectively [1]. While low-cost beta
blockers (BB) and diuretics were recommended for many
patients, other antihypertensive drug classes were suggested for
use in speciﬁc clinical situations and for patients with comorbidi-
ties. For example, the favorable effects of the angiotensin-
converting enzyme inhibitors (ACEI) on heart failure and type 1
diabetes nephropathy categorized the ACEI as compelling for
these indications [1,2]. Also, using at least two antihypertensive
drugs was more strongly emphasized to achieve BP targets [1,2].
At the time of the initial ARB launches, the evidence demon-
strated ARBs to have similar BP-lowering efﬁcacy compared with
competitors [3–5]. Thus, the role of the ARB class was uncertain
because ARBs did not per se meet unmet medical need and in the
absence of long-term data, the only compelling indication for
ARB therapy was for cases involving ACEI intolerance [1,2].
Although ACEI and ARBs both clinically manipulate the renin
angiotensin system, ARBs are less likely to cause cough, a side
effect that affects up to 16% of patients on ACEI therapy
[3,4,6–9]. ARBs have high tolerability compared with their com-
petitors [3–15] with ARB side effects referred to as generally mild
[16]. Additionally, the ARBs have a low interaction proﬁle with
other drug treatments [17]. While ARBs appeared to have a
favorable side effect proﬁle, they were introduced at a premium
price, compared with several existing hypertension drugs [18],
which had well-established evidence of effectiveness.
Prior to the adoption of new drug therapies on the national
formulary, regulatory agencies, including the National Institute
for Health and Clinical Excellence (NICE) [19] in the UK, have
begun to request budget impact analysis of newdrugs prelaunch to
estimate the ﬁnancial impact of drug approval on health-care
budgets. These analyses require drug use forecasting, as well as the
new drugs’ impact on existing therapeutic mix [20]. New thera-
pies often predict budget increases. The unclear role of the ARBs
would have challenged the forecasting, resulting in imprecise
budget impact estimates. Because of the increasing pressure on the
National Health System (NHS) for new,more effective and expen-
sive therapies, NICE recommends performance of postlaunch
studies in order to examine how drugs are used in actual practice
[21,22].
The ﬁnancial impact of ARB introduction has not been evalu-
ated post-launch. Therefore, using The Health Improvement
Network (THIN) primary care database, this study aimed to
evaluate the trends in ARB prescribing and their antihypertensive
drug budget impact as the ﬁrst ARB market launch to present
time. The analysis also estimated the speciﬁc proportion of the
budget increase that was directly attributable to the ARBs and
evaluated product shift and drug utilization factors over time,
which impact drug expenditure [23].
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Methods
To consider all potential ARB competitors for comparison [20],
all prescriptions for oral hypertension treatments were identiﬁed
from January 1995 through July 2004 in the THIN database, an
electronic medical record dataset of approximately 3 million
patients seen in more than 220 general practices across the UK.
The data are continuously updated providing patient level lon-
gitudinal medical records including demographic, medical, pre-
scription, laboratory, referrals to specialists, hospitalization,
lifestyle characteristics, clinical measurements, and socioeco-
nomic information. THIN has been proven a valid data source
for research [24,25] and recording behavior among the General
Practitioners (GPs) providing data for THIN approximates the
national level [26]. Oral antihypertensive drugs were identiﬁed
using British National Formulary treatment class codes:
02.02.01–02.02.04 and 02.02.08 (diuretics), 02.04.00 (BB),
02.05.01–02.05.04 (vasodilators, centrally acting drugs, adren-
ergic neuron blocking drugs, and alpha blockers, which all were
labeled as “other”), 02.05.05.01 (ACEI), 02.05.05.02 (ARB),
and 02.06.02 calcium channel blockers (CCB) [16]. Drug prices
were based on the Chemist & Druggist January 2005 pricelist
[27], which only provides brand prices (without sales tax). The
use of 2005 prices rather than historical prices was used to
estimate real growth in drug expenditure from the NHS payer
perspective [20]. A per tablet price was estimated and multiplied
by the number of tablets issued on each prescription. As budgets
are generally estimated on an annual basis [20], annual estimates
were derived for 1995 and each subsequent year. Estimates for
year 2004 were annualized by multiplying by 12/7 to account for
the fact that only 7 months of data were available for 2004. The
annual antihypertensive drug use cohort consisted of patients
receiving at least one antihypertensive prescription in that year.
Expenditure trends were disaggregated for each calendar year by:
1) treatment prevalence, deﬁned as the number of patients receiv-
ing at least one antihypertensive prescription out of all midyear
registered patients in THIN (a utilization measure); 2) average
number of antihypertensive prescriptions per patient (a utiliza-
tion measure); and 3) average drug expenditure per antihyper-
tensive prescription (a product shift measure that leads to real
inﬂation). Thus, the overall ARB market life drug budget impact.
estimate =
× × ×( ) − × × ×x y z u x y z u2004 2004 2004 2004 1995 1995 1995 1995( ) (1)
where,
x: Average drug expenditure per antihypertensive prescription.
y: Average number of antihypertensive prescriptions per patient.
z: Treatment prevalence.
u: UK population size, midyear.
A comparison of x with and without the ARB expenditure
included constituted the estimation of the direct antihypertensive
drug budget impact of the ARBs. The difference between generic
prices and brand prices in the UK ranges from 0% to 80%, with
the latter ﬁgure for a few antihypertensive products [16]. We
estimated that within classes, where some of the products have
generic competition, the average drug expenditure would be
20% reduced if having access to both brand and generic prices
compared with including brand prices only. Furthermore, the
year 2001 total antihypertensive drug cost estimate (x2001 ¥
y2001 ¥ z2001 ¥ u2001) of £1047.5 (2005 Great British Pound value)
is 20% higher than a literature identiﬁed estimate of £840
million (2001 Great British Pound value) from 2001 [28] when
not adjusted for consumer price inﬂation, and 10% higher when
adjusted. Therefore, for sensitivity analysis, a 20% reduction in
ARB drug expenditure and a 20% reduction in drug expenditure
for the remaining classes to estimate the impact of lack of access
to generic drug prices were applied.
We also evaluated how much of the increase in average anti-
hypertensive drug expenditure over time per patient n:
nt t tx y t= × =, , , . . .1995 1996 2004 (2)
was due to: 1) increased drug expenditure per anti-hypertensive
prescription x (product shift); and 2) increased number of anti-
hypertensive prescription per patient y (utilization). We applied
year 1995 average expenditure per prescription x1995 across all
years:
nt x tx y t1995 1995 1995 1996 2004( ) = × =, , , . . . (3)
where nt(x1995) equals average antihypertensive drug expenditure
per patient in a given year t with x kept constant over time using
the year 1995 estimate. Year 1995 is used as the base year
because it was the ﬁrst year of ARB utilization. After, nt and
nt(x1995) were compared with estimate the impact of product shift
x and utilization y on the real rate of drug expenditure n increase
over time. The difference between nt and nt(x1995) constitutes the
impact of a product shift x toward use of more expensive drugs.
This is because utilization yt is identical in both equations in a
given year. The difference between n1995 and nt(x1995) constitutes
the impact of utilization y. This is because x is identical (x1995) in
both equations. For sensitivity analysis, a 20% reduction in drug
expenditure for all antihypertensives except those in the ARB
class was applied to x.
Results
A total of 24,438,824 prescriptions for hypertension treatment
were identiﬁed from the THIN data during the time period from
January 1, 1995 to July 2004. ARB prescription frequency
increased from 0.04% in 1995 to 6.57% in 2004 (Fig. 1). Pre-
scription frequencies also increased over time for ACEI and
“other” classes and decreased for diuretics, BB, and CCB (Fig. 1).
The prescription volume growth rate was positive for the
ARBs and large in magnitude, especially in the early years after
the ﬁrst ARB was introduced to the market (Table 1). The ACEI
and “other” classes also had a positive growth rate during the
study time period where the ACEI growth rate changed the most
between 1996 and 1997 going from 9.60% to 5.35%. The
remaining treatment classes had a negative or almost no prescrip-
tion growth over time, with CCB and diuretics both having their
most negative growth in 2002 at -3.59% and -3.68%, respec-
tively (Table 1).
Treatment prevalence rose from 11.30% in 1995 to 16.90%
in 2004 (Table 2), while the average number of antihypertensive
drug prescriptions per patient increased from 9.34 to 13.46 per
year, respectively (Table 2). The average antihypertensive drug
expenditure per antihypertensive prescription increased over
time reﬂecting a product shift toward more expensive therapies
(Fig. 2, “With ARBs” graph). The average antihypertensive drug
expenditure per patient increased from £71 in 1995 to £144
in 2004 (2005 Great British Pound values) (Fig. 3, “Identiﬁed
expenditure per Rx” graph).
The expenditure for antihypertensive drugs was estimated at
£465,862,416 in 1995 and £1,458,268,104 in 2004 (2005 Great
British Pound values), reﬂecting an overall drug budget impact of
£992,405,688. This represents a 213% real rate of increase
during the ﬁrst 10 years of the ARBs’ market life. Use of ARBs
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accounted for 9.3% of the average drug expenditure. Using a
20% reduction in ARB drug expenditure for sensitivity analysis,
ARBs accounted for 5.8% in 2004 providing a range from 5.8%
to 9.3%. Applying the 20% drug expenditure reduction for the
remaining classes resulted in ARB use accounting for 9.4% to
12.5%.
In 1997, the real increase in average drug expenditure per
patient was £7.6 (relative to 1995). Of these, £4.7 (62.3%) was
due to product shift (i.e., use of more expensive prescriptions)
and £2.9 (37.7%) was due to increased utilization (i.e., number
of prescriptions per patient) (Fig. 3). In 2004, the real expendi-
ture increase was £73.1, of which £41.8 (57.2%) was due to
product shift and £31.3 (42.8%) was due to increased utilization
(Fig. 3). The sensitivity analysis revealed a £4.1 (64.2%) and
£2.3 (35.8%) product shift and utilization impact, respectively,
in 1997. In 2004, the ﬁgures were £37.8 (60.2%) and £25.0
(39.8%), respectively.
Discussion
Angiotensin II receptor blocker prescribing frequency identiﬁed
across the ﬁrst decade of the ARB market life was lower than
expected. Therefore, GPs in the UK seemed to have prescribed
ARBs with caution and may not have viewed ARBs as providing
distinct advantages over competing classes. UK GPs have a posi-
tive attitude toward innovative products, but only use them when
existing treatments fail to work [29]. This seems to be the case
for ARB use, where well-known alternatives existed for hyper-
tension, which, until 2002, was the only approved indication for
ARBs. Various ARBs have been studied [12,30–34] in different
patient populations and some ARBs have since been approved
for other indications, such as renal disease and heart failure [35].
The renal disease indication took effect in 2002, but this did not
coincide with a signiﬁcant increase in prescribing most likely
because ACEI already had become an established treatment
option for patients with renal disease. Importantly, many treat-
ment guidelines advise ARB use only as a default for patients
who do not tolerate ACEI therapy [1,2,36–38]. Furthermore, the
ARBs are expensive relative to other antihypertensive drugs and
did not have generic competition during the study period. As
generics are widely used in the UK [39], the lack of generic
competition could also explain the modest ARB uptake. Finally,
GPs could be late adopters [40] of the ARBs, meaning that the
rate of adoption of this class is slower.
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Figure 1 Fequency of antihypertensive drug prescriptions by drug class and year.ACEI, angiotensin-converting enzyme inhibitor;ARB, angiotensin II receptor blocker;
BB, beta-blocker; CCB, calcium channel blocker.
Table 1 Prescription growth rate by treatment class with previous year as base year (annual growth)
Year class 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2004 vs. 1995
ARB* — 494.93% 166.47% 105.20% 56.50% 36.31% 29.21% 30.17% 20.76% 12.27% 15,725%
ACEI — 9.60% 5.35% 2.59% 2.41% 1.85% 2.84% 3.64% 1.31% 1.62% 36%
CCB — -0.08% -0.98% -1.73% -3.32% -3.52% -3.35% -3.59% -2.79% -0.75% -18%
BB — -2.72% -2.17% -0.84% -0.09% 0.03% -0.38% -1.08% -1.10% -0.19% -8%
Diuretics — -2.74% -1.80% -2.23% -2.63% -2.47% -2.79% -3.68% -1.89% -2.81% -21%
“Other” — 2.94% 3.23% 7.14% 13.19% 11.47% 7.02% 6.48% 1.38% 0.01% 66%
*The growth rates are high for the ARBs because they are new in the market.The growth rates are based on annual prescription frequencies shown in Figure 1.
ACEI, angiotensin-converting enzyme inhibitor;ARB, angiotensin II receptor blocker; BB, beta blocker; CCB, calcium channel blocker.
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The 213% real rate of antihypertensive drug expenditure
increase during the ﬁrst 10 years of the ARB market life cannot
solely be explained by the introduction of ARBs. The ARBs
accounted for only a trivial portion of expenditure right after the
ﬁrst launch and grew to about 5% to 12.5% of the direct
antihypertensive drug costs in 2004. Product shift to other anti-
hypertensive classes and increased utilization because of reduc-
tion in BP targets and more emphasis on using antihypertensive
therapies in combination likely explain the majority of the
budget increase. Furthermore, during 2003 a new GP reimburse-
ment scheme was approved [41]. This scheme, enacted April 1,
2004, ﬁnancially rewards GPs for achieving BP targets [42]. This
could have reinforced focus on BP targets and means to reach
them including increased drug utilization.
This case study of ARBs illustrates that the introduction of
new,more expensive technologies is not necessarily themain cause
of in-class budgetary increases and illustrates how post hoc analy-
ses of drug introductions may vary from both expectation and
prelaunch budget impact analyses. The budget increase might
happen regardless of the new therapy introduction because of
utilization changes in the existing therapeutic mix, which can be
initiated by treatment guideline changes. Furthermore, epidemio-
logical factors resulting in increased disease prevalence (e.g.,
obesity and ageing population) also impact budgets. Therefore,
these ﬁndings highlight the importance of forecasting the utiliza-
tion patterns of the existing therapeutic mix, as well as disease
prevalence in prelaunch budget impact models [20]. When ARBs
ﬁrst entered the antihypertensivemarket, theARB class had strong
competition, especially from the ACEI class, which appeared to be
only slightly less tolerable than the ARBs. Therefore, it most likely
could have been predicted, based upon clinical trial information at
the time of ARBmarket entry, that UKGPs would prescribe ARBs
sparingly if ARBs came with a premium price. This is particularly
true because there are ﬁnancial incentives [43,44] that motivate
GPs in the UK to utilize less expensive medications if they provide
equivalent efﬁcacy.Dynamic factors in society, epidemiological, or
political factors that impact future disease prevalence or treatment
are important components for designing the structure of budget
impact models. Creating a ﬂexible model, where different plau-
sible scenarios can be evaluated, is recommended by the Interna-
tional Society for Pharmacoeconomics and Outcomes Research
(ISPOR) Task Force on Good Research Practices—Budget Impact
Analysis [20]. This study found that the treatment prevalence,
average number of antihypertensive prescriptions, and the average
cost per prescription all increased over time, impacting the drug
budget in an upward direction.
Treatment Prevalence
Changes in hypertensive practice guidelines could explain the
increasing treatment prevalence over time, especially between
1999 and 2000, where the annual increase was the highest at
6.41% (Table 2). Furthermore, approximately 46% of UK adults
are overweight and the prevalence of obesity has increased more
rapidly in the UK as compared with other European countries
with identical lifestyle patterns [45]. From 1980 to 1998, the
prevalence of obese (body mass index 30 kg/m2) UK citizens
nearly tripled to 21% of women and 17% of men. There was no
indication that this trend would change. As being overweight is a
risk factor for cardiovascular disease [45], and obese patients are
more likely to receive anti-hypertensive medication [46], this
trend in prevalence of overweight in the UK may also have
contributed to the result. The size of the UK population increased
during the study time and, consequently, more people would
likely receive antihypertensive treatment.Ta
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Average Number of Antihypertensive Prescriptions
Per Patient
On average, patients did receive more prescriptions over time
(Table 2), which is an important factor that explains some of the
drug budget increase. In the 1993 British hypertension treatment
guidelines, combining antihypertensives was suggested as a strat-
egy if the ﬁrst drug was only partially effective [47]. However, the
1999 hypertension treatment guidelines explicitly stated that in
order to achieve the recommended BP target, a combination of
antihypertensive drugs would be required for the majority of
patients and, in 2003, Brown et al. published speciﬁc guidelines
on how the antihypertensive drug classes should be combined
[1,48]. Interestingly, from 1999 to 2001, the average number of
prescriptions per patient increased sharply, indicating that the
GPs followed these recommendations of prescribing multiple
drugs from different classes (i.e., drug combination therapy).
Between 1995 to 1997 and 2001 to 2003, on average 35.70%
patients and 51.49% patients, respectively, received drug pre-
scriptions from more than one of the anti-hypertensive classes.
However, a proportion of these patients could have received the
drugs sequentially and not necessarily simultaneously, that is, in
combination. British guidelines also recommend using multiple
agents across different antihypertensive classes for treatment of
heart failure [37]. As many anti-hypertensive drugs also have a
heart failure indication, this would reinforce the increase in the
average number of prescriptions per patient over time and
thereby accelerate the budgetary impact.
Average Drug Expenditure Per
Antihypertensive Prescription
The increase over time in the average expenditure across all
classes per prescription (Fig. 2) is explained by the shift in use
from lower-cost drug classes to the more expensive drug classes.
The shift over time is demonstrated in Table 1 where two of the
most expensive treatment classes, ARB and ACEI, had positive
growth in terms of prescription frequencies, whereas the less
expensive classes, BB and diuretics, had negative growth over
time. The decreased use of BB and diuretics and the increased use
of ACEI have been identiﬁed as far back as the 1980s in US
health-care settings [49,50]. This product shift leads to a real rate
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base year. B: Change in drug expenditure from the
1995 baseline because of use of more expensive
drugs (product shift) (£4.7 [62.3%]). C: Change in
drug expenditure from the 1995 baseline because
of use of more prescriptions per patient (utiliza-
tion) (£2.9 [37.7%]). D: £73.1 real expenditure
inﬂation with 1995 as the base year. E: Change in
drug expenditure from the 1995 baseline because
of use of more expensive drugs (product shift)
(£41.8 [57.2%]). F: Change in drug expenditure
from the 1995 baseline because of use of more
prescriptions per patient (utilization) (£31.3
[42.8%]).
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of inﬂation and is an important factor contributing to the
increased antihypertensive drug budget during the ﬁrst 10 years
of the ARBs market life.
Product Shift and Utilization Impact on Average
Antihypertensive Drug Expenditure
Over time, prescription utilization increases played a bigger role
in driving expenditure trends. The increase in expenditure attrib-
utable to prescription utilization was 37.7% shortly after the ﬁrst
ARB launch and rose to 42.8% in 2004. The increase in expen-
diture attributable to product shift was 62.3% initially after ARB
launch and declined to 57.2% in 2004 (Fig. 3). Thus, prescrip-
tion utilization constituted the smallest part of the expenditure
increase in comparison with product shift, but over time pre-
scription utilization enlarged its share of the expenditure increase
from 37.7% to 42.8%. This was relative to product shift whose
share of the expenditure increase declined from 62.3% to 57.2%.
The growing role of prescription utilization on expenditure
trends may be explained by the changes in hypertension treat-
ment guidelines [1]. In particular, the revised guidelines recom-
mended greater use of multiple antihypertensive therapies. The
new guidelines did recommend treatment with the relatively
more expensive classes such as ACEI and CCB for speciﬁc popu-
lations, but for newly diagnosed patients with no comorbidities
to hypertension, treatment with the less expensive classes like BB
and diuretics was recommended [1].
Limitations of the Study
This study did not have access to generic drug prices and, there-
fore, applied brand prices to all anti-hypertensive prescriptions
identiﬁed in the data. In the UK, generic penetration is high [39].
Because of the lack of access to generic prices, the annual antihy-
pertensive drug expenditure has been somewhat overstated by
10% to 20%, and the antihypertensive drug budget impact
(formula 1) has been somewhat understated as applying the 20%
expenditure reduction for all classes except the ARBs reveals a
224% overall ARB market life drug budget impact. Finally, the
direct impact of ARBs has been slightly underestimated as this
drug class does not have generic competition. However, a sensi-
tivity analysis that examined the impact of using 20%discount for
drug classes with generic competition deviated only slightly from
the study results. The sensitivity analysis revealed an up to 12.5%
direct antihypertensive drug budget impact of the ARBs whereas
the study result was 9.3%. Another limitation relates to the fact
that the analysis refers to issued prescriptions, some of which
would not have been ﬁlled.
Conclusion
Angiotensin II receptor blockers accounted for only 9.3% (range:
5.8%–12.5%) of the 213% increase in real expenditure on anti-
hypertensive drugs after the introduction of ARBs in the UK. A
substantial portion of the impact reﬂected increases in treatment
prevalence and in the number of prescriptions per patient, includ-
ing the use of multiple antihypertensive therapies. Furthermore,
use of ACEI, a major competitor to the ARBs and a relatively
expensive class, increased signiﬁcantly, whereas use of lower cost
anti-hypertensive drug classes decreased. These results reveal a
product shift over time toward more costly classes in general, but
not ARBs in particular. Prescription utilization constituted an
increasing part of the antihypertensive drug expenditure increase
over time. Product shift constituted a decreasing part of the drug
expenditure increase over time. The policy implications of these
ﬁndings are that future drug budget impact analyses have to
consider trends in the use of competitive drugs as well as treat-
ment prevalence, where treatment prevalence over time could be
inﬂuenced by new treatment guidelines and the dynamics of the
health status and demographics of the population.
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